Online citations, reference lists, and bibliographies.
← Back to Search

Docetaxel (Taxotere): A Review Of Preclinical And Clinical Experience. Part I: Preclinical Experience.

M. Bissery, G. Nohynek, G. Sanderink, F. Lavelle
Published 1995 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Docetaxel is a taxoid which is currently in phase II/III clinical trials in Europe, the US and Japan. It was found to promote tubulin assembly in microtubules and to inhibit their depolymerization. In vitro, the docetaxel concentrations required to reduce murine and human cell survival by 50% ranged from 4 to 35 ng/ml and the cytotoxic effects were greater on proliferating than on non-proliferating cells. It was also found to be cytotoxic on fresh human tumor biopsies. In vivo, the drug was found to be schedule independent. A total of 13/14 murine transplantable tumors were found very sensitive to i.v. docetaxel and complete regressions of advanced stage tumors were obtained. Activity was also observed in 15/16 human tumor xenografts in nude mice at an advanced stage. In combination studies, synergism was observed in vivo with 5-fluorouracil, cyclophosphamide and etoposide. Pharmacokinetic evaluation revealed linear pharmacokinetics in tumor-bearing mice. There was a good tumor retention with a 22 h elimination half-life. Plasma protein binding ranged from 76 to 89%. Preclinical toxicology evaluation of docetaxel included single-dose toxicity in rats, mice and dogs, 5-day toxicity in mice and dogs, intermittent-dose toxicity in rats, dogs and monkeys, genetic and reproductive toxicity, as well as investigation of the irritation and sensitization potential. The principal toxicities were hematopoietic (all species), gastrointestinal (dog, monkey) and neuromotor (mice). Dogs appeared to be the most sensitive species. The clinical entry dose of 5 mg/m2 was based on one-third of the 'toxic dose low' in dogs (15 mg/m2).



This paper is referenced by
10.1016/B978-0-12-819874-2.00008-4
Curious effects of fluorine on medicinally active compounds
T. Honda (2021)
10.1590/S2175-97902020000118996
Paclitaxel and spirulina co-loaded polymeric nanoparticles: in-vitro and in-vivo anticancer study
Yamuna Ravikumar (2021)
10.1016/j.drup.2021.100754
Therapeutic strategies to overcome taxane resistance in cancer.
Tuyelee Das (2021)
10.1016/J.MTNANO.2021.100115
Supramolecular PEGylation of camptothecin for cancer therapy
R. Sun (2021)
10.21608/EJCHEM.2021.60640.3305
Design, Synthesis, Characterization and Anticancer Evaluation of Novel Mixed Complexes Derived from 2-(1H-Benzimizadol-2-yl)aniline Schiff base and 2-Mercaptobenzimidazole or 2-Aminobenzothiazole
F. Alminderej (2021)
10.1007/978-981-15-8179-3
Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy
S. A. Ganai (2020)
10.1007/978-981-15-8179-3_6
Compendium of Mechanistic Insights of Distinct Conventional Anticancer Therapies and Their Grievous Toxicities
S. A. Ganai (2020)
10.37871/ajpt.id19
Docetaxel Formulation in Polysorbate 80: A Complex and Sensitive System
J. Authelin (2020)
10.3390/polym11091422
Molecular Mechanisms of Antitumor Activity of PAMAM Dendrimer Conjugates with Anticancer Drugs and a Monoclonal Antibody
Monika Marcinkowska (2019)
10.4103/aja.aja_37_18
Impact of taxanes on androgen receptor signaling
S. Bai (2019)
10.1016/j.jconrel.2018.11.013
Reviewing two decades of nanomedicine implementations in targeted treatment and diagnosis of pancreatic cancer: An emphasis on state of art
S. A. El-Zahaby (2019)
10.3390/ijms20030586
The Potential of Combining Tubulin-Targeting Anticancer Therapeutics and Immune Therapy
A. Fong (2019)
10.1038/s41551-018-0234-x
Micelles with ultralow critical micelle concentration as carriers for drug delivery
Y. Lu (2018)
10.18535/jmscr/v6i9.157
A Study of Paclitaxel Induced Acute Pain Syndrome: A Prospective Study done at State Cancer Institute J&K
Dar Abdul Waheed (2018)
10.1007/978-3-319-78762-6_7
Molecular Regulation of Cell Cycle and Cell Cycle-Targeted Therapies in Head and Neck Squamous Cell Carcinoma (HNSCC)
E. Demidova (2018)
10.1007/s10928-018-9586-9
Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics
X. Zang (2018)
10.1186/s12957-018-1400-z
Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways
Ashley B. Ward (2018)
10.1159/000481339
Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience
E. El Rassy (2018)
10.1093/chromsci/bmy064
A Rapid and Precise Liquid Chromatographic Method for Simultaneous Determination of Alpha Lipoic Acid and Docetaxel in Lipid-Based Nanoformulations.
Ishit R Kothari (2018)
10.1007/978-3-319-78762-6
Molecular Determinants of Head and Neck Cancer
B. Burtness (2018)
10.1016/j.jconrel.2017.03.027
Developments and future clinical outlook of taxane nanomedicines.
B. Louage (2017)
10.15369/SUJMS.29.69
Comparing the Adverse Event Profiles of Nivolumab and Docetaxel in Previously-treated or Refractory Advanced Non-small Cell Lung Cancer: A Meta-analysis of Two Phase 3 Trials
Ando Koichi筆頭著者責任著者 (2017)
10.22377/IJGP.V11I03.1188
Development of novel docetaxel-loaded gelatin nanoparticles for intravenous application: Hemolytic activity, hematological study, and biodistribution profile or in vivo cancer study
A. Jain (2017)
10.1007/978-1-4939-6646-2
Cancer Nanotechnology
R. Zeineldin (2017)
10.1007/978-1-4939-6646-2_26
Radiosensitizing Silica Nanoparticles Encapsulating Docetaxel for Treatment of Prostate Cancer.
J. Belz (2017)
Title Disposition kinetics of taxanes in peritoneal dissemination
K. Miyamoto (2017)
10.1016/j.jfluchem.2016.12.016
Strategic Incorporation of Fluorine into Taxoid Anticancer Agents for Medicinal Chemistry and Chemical Biology Studies.
I. Ojima (2017)
10.2147/IJN.S140073
Design of theranostic nanomedicine (II): synthesis and physicochemical properties of a biocompatible polyphosphazene–docetaxel conjugate
Y. Jun (2017)
10.4032/9789814669214
Design and development of approved nanopharmaceutical products
Raj Bawa (2016)
Stealth poly(lactic-co-glycolic acid) - diiodinated boron dipyrromethene nanoparticles to improve tumour selectivity in photodynamic cancer therapy /Voon Siew Hui
Siew Hui Voon (2016)
10.1186/s13046-016-0351-x
Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
P. Wang (2016)
10.1016/j.carbpol.2015.10.012
Fabrication, characterization and cytotoxicity studies of ionically cross-linked docetaxel loaded chitosan nanoparticles.
Ankit Jain (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar